The influence of cisapride on gastric tone and the perception of gastric distension

Tack, Jan; Broeckaert, D; Coulie, Bernard; Janssens, Jozef

doi:10.1046/j.1365-2036.1998.00366.x

Cited by 126 publications

(104 citation statements)

References 19 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Pretreatment with cisapride was shown to significantly enhance the accommodation to a meal in healthy subjects, suggesting potential benefit of 5-HT 4 receptor agonists in patients with impaired gastric accommodation. 78 More recently, a relaxatory effect on the proximal stomach was confirmed for the 5-HT 4 receptor agonist tegaserod. 79 We have shown that administration of sumatriptan, a 5-HT 1 receptor agonist, also relaxes the proximal stomach in healthy subjects 80 and, in acute studies, is able to restore the meal-induced relaxation in patients with impaired gastric accommodation and to increase the amount of calories ingested at maximum satiety in patients with early satiety.…”

Section: Fundus-relaxing Drugsmentioning

confidence: 93%

“…88 However, the selective 5-HT 3 antagonists alosetron and ondansetron do not appear to have any significant effects on sensitivity to gastric distension in humans. 89,90 A recent study demonstrated reduction in dyspeptic symptoms in functional dyspepsia patients treated with alosetron. 91 The mechanism underlying this beneficial effect remains to be elucidated, but additional studies with alosetron are unlikely because this drug has been withdrawn due to side effects.…”

Section: Antinociceptive Agentsmentioning

confidence: 99%

“…92 As this drug does not alter gastric tone or sensitivity, it is likely to be act at duodenal vagal afferents. 89,90 Although efficacy has to be established, pharmacologic modulation of upper gut sensitivity appears promising for the development of novel treatment of functional dyspepsia.…”

Section: Antinociceptive Agentsmentioning

confidence: 99%

See 2 more Smart Citations

Pathophysiology and Treatment of Functional Dyspepsia

Tack

Lee

2005

Journal of Clinical Gastroenterology

207

247

View full text Add to dashboard Cite

Functional dyspepsia is a highly prevalent symptom complex and a heterogenous disorder. Recent studies showed potential associations between specific pathophysiologic disturbances and dyspeptic symptoms. Delayed gastric emptying reported in about 30% of patients with functional dyspepsia is associated with the symptoms of postprandial fullness, nausea, and vomiting. Impaired gastric accommodation present in 40% of functional dyspepsia patients is found to be associated with early satiety. Hypersensitivity to gastric distension is observed in 37% of functional dyspepsia patients and associated with the symptoms of postprandial pain, belching, and weight loss. Psychosocial factors and altered response to duodenal lipids or acid have also been identified as pathophysiologic mechanisms. Therapeutic options are still limited but targeted therapy directed at the underlying pathophysiology seems desirable. Thus, efforts to further elucidate underlying pathophysiologic mechanisms and identify the appropriate patient population using some type of pathophysiologic testing will be required.

show abstract

Section: Fundus-relaxing Drugsmentioning

confidence: 93%

Section: Antinociceptive Agentsmentioning

confidence: 99%

See 1 more Smart Citation

Pathophysiology and Treatment of Functional Dyspepsia

Tack

Lee

2005

Journal of Clinical Gastroenterology

207

247

View full text Add to dashboard Cite

show abstract

“…29) Previous studies suggested that the activity of CTE and its main component, corydaline, may be related to the 5-HT 4 receptor because the 5-HT 4 receptor agonists cisapride and tegaserod are known to accelerate GE and small bowel transit and enhance gastric accommodation in humans. [32][33][34][35][36] Furthermore, corydaline has weak affinity for the 5-HT 1A , 5-HT 1B , and non-selective 5-HT 1 receptor subtypes (pK i Ͻ5; data not shown), thus excluding the 5-HT 1 receptors from the gastric-relaxing effect. Further study is necessary to clarify the mechanisms of action of corydaline.…”

Section: )mentioning

confidence: 99%

Effects of Corydaline from Corydalis Tuber on Gastric Motor Function in an Animal Model

Lee

Son

Kim

2010

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Functional dyspepsia (FD) is a highly prevalent chronic gastrointestinal (GI) disorder that causes a considerable burden to both the patient and society. Although the etiology and pathogenesis of FD are poorly understood, FD is associated with pathophysiologic abnormalities including delayed gastric emptying (GE), impaired gastric accommodation, and visceral hypersensitivity.1,2) Delayed GE has been reported in 30-40% of FD patients, 3) and a number of studies have demonstrated impaired gastric accommodation after meals in approximately 40% of patients. 4) Given these results, we hypothesized that GE of a semi-solid meal, GI transit, and gastric accommodation would be suitable markers for evaluating motor effects in animal models.Corydalis tubers, the roots of Corydalis yahusuo W.T. WANG (Papaveraceae), have long been used as herbal medicine for their analgesic and anti-ulcer effects. It has been reported that Corydalis tuber extracts exhibit several biological activities, acting as both an anti-spasmodic agent in the GI tract and as an analgesic. [5][6][7][8] Previous phytochemical studies reported that Corydalis tubers are made up primarily of alkaloid compounds including corydaline, berberine, protopine, and palmatine. [8][9][10][11][12] These alkaloid compounds are reported to provide the analgesic, anti-spasmodic, and anti-acetylcholinesterase activities associated with Corydalis tubers. Of these compounds, corydaline is considered the marker compound for quality control of Corydalis extract; however, the pharmacological effects of corydaline on GI motor function have not yet been studied.We previously investigated the prokinetic activities of corydaline to determine its potential bioactivity in FD and elucidated the basis of the selection of corydaline as the principal marker compound for quality control. 13) In the present study, we evaluated the effects of corydaline on GE and GI transit in rats and gastric accommodation in conscious dogs. MATERIALS AND METHODS Plant MaterialPlant material was commercially purchased at Kyungdong herbal market (Seoul, Korea) and identified by Dr. S. Choi at the Research Center of Dong-A Pharm. Co., Ltd. (Yongin-si, Korea). A voucher specimen has been deposited in our laboratory at Kyung Hee University.Extraction and Isolation Dried Corydalis tuber (30 kg) was extracted with 50% aqueous ethanol three times at room temperature. Upon removal of the solvent under vacuum, the ethanolic extract yielded 2.85 kg of material (Corydalis tuber extract, CTE; 7.6% by dry weight). We found that the CTE contained corydaline, palmatine, berberine, and other isoquinoline alkaloids. Based on HPLC analysis, the prescribed range of index components including corydaline and palmatine was detected in the CTE. The CTE was suspended in H 2 O and partitioned successively with n-hexane, ethyl acetate (EtOAc), and n-butanol. The EtOAc-soluble fraction (15 g) of the extract was subjected to a silica gel column using mixtures of n-hexane-EtOAc of increasing polarity as eluents to give 12 sub-fraction...

show abstract

“…This could explain the variety of drugs which show a positive symptomatic response [1] , currently there is no FDA-approved drug for treatment of FD [3] . Despite the scant evidence, anti-secretory agents are frequently recommended in the treatment of patients with a predominant complaint of pain while prokinetic agents are frequently used for bloating and early satiety [4] . Patients' symptoms that are severe enough to disrupt daily activities will likely benefit from pharmacologic therapy.…”

Section: Introductionmentioning

confidence: 99%